Cargando…

Anti-G protein antibodies targeting the RSV G protein CX3C chemokine region improve the interferon response

BACKGROUND: Respiratory syncytial virus (RSV) is a poor inducer of antiviral interferon (IFN) responses which result in incomplete immunity and RSV disease. Several RSV proteins alter antiviral responses, including the non-structural proteins (NS1, NS2) and the major viral surface proteins, that is,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bergeron, Harrison C., Kauvar, Lawrence M., Tripp, Ralph A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Respiratory Syncytial Virus Infection
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017941/ https://www.ncbi.nlm.nih.gov/pubmed/36938145 http://dx.doi.org/10.1177/20499361231161157

Ejemplares similares

Review of respiratory syncytial virus infection among older adults and transplant recipients
por: Villanueva, Daphne-Dominique H., et al.
Publicado: (2022)

Bronchiolitis hospitalizations in rural New England: clues to disease prevention
por: Wright, Peter F., et al.
Publicado: (2022)

Clinical and biological consequences of respiratory syncytial virus genetic diversity
por: Rios Guzman, Estefany, et al.
Publicado: (2022)

Community-based asthma assessment in young children: adaptations for a multicentre longitudinal study in South Asia
por: Islam, Mohammad Shahidul, et al.
Publicado: (2022)

Comparison of clinical presentations and burden of respiratory syncytial virus in infants across three distinct healthcare settings in Davidson County, Tennessee
por: Rankin, Danielle A., et al.
Publicado: (2022)

RSV Replication, Transmission, and Disease Are Influenced by the RSV G Protein
por: Bergeron, Harrison C., et al.
Publicado: (2022)

Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein
por: Bergeron, Harrison C., et al.
Publicado: (2023)

Respiratory Syncytial Virus (RSV) G Protein Vaccines With Central Conserved Domain Mutations Induce CX3C-CX3CR1 Blocking Antibodies
por: Bergeron, Harrison C., et al.
Publicado: (2021)

Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge
por: Powell, Thomas J., et al.
Publicado: (2022)

Healthy but not RSV-infected lung epithelial cells profoundly inhibit T cell activation
por: Wang, H, et al.
Publicado: (2009)

Nanoparticle Vaccines Encompassing the Respiratory Syncytial Virus (RSV) G Protein CX3C Chemokine Motif Induce Robust Immunity Protecting from Challenge and Disease
por: Jorquera, Patricia A., et al.
Publicado: (2013)

Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and Disease
por: Jorquera, Patricia A., et al.
Publicado: (2015)

Clinical phenotypes and outcomes of SARS-CoV-2, influenza, RSV and seven other respiratory viruses: a retrospective study using complete hospital data
por: Hedberg, Pontus, et al.
Publicado: (2022)

Immunopathology of RSV: An Updated Review
por: Bergeron, Harrison C., et al.
Publicado: (2021)

Role of Type I Interferon (IFN) in the Respiratory Syncytial Virus (RSV) Immune Response and Disease Severity
por: Hijano, Diego R., et al.
Publicado: (2019)

G-Protein-Coupled Receptor and Ion Channel Genes Used by Influenza Virus for Replication
por: Orr-Burks, Nichole, et al.
Publicado: (2021)

Toll-like receptor 7 governs interferon and inflammatory responses to rhinovirus and is suppressed by IL-5-induced lung eosinophilia
por: Hatchwell, Luke, et al.
Publicado: (2015)

Immunogenicity and protective efficacy of an RSV G S177Q central conserved domain nanoparticle vaccine
por: Bergeron, Harrison C., et al.
Publicado: (2023)

Working with Respiratory Illness: Presenteeism Among Healthcare Personnel at Tertiary-Care Hospitals in Bangladesh, 2008–2016
por: Mah-E-Muneer, Syeda, et al.
Publicado: (2021)

Healthcare-associated respiratory syncytial virus infections in children’s hospitals
por: Saiman, Lisa, et al.
Publicado: (2022)

Assessing alternatives to HEPA air purification requirements to reduce viral pathogen transmission in healthcare HVAC systems
por: Bischoff, Werner, et al.
Publicado: (2022)

Respiratory Virus infections in symptomatic and asymptomatic children: Results of one year of hospital admission screening
por: Most, Zachary, et al.
Publicado: (2022)

Clinical factors associated with antibiotic de-escalation after a positive multiplex molecular respiratory panel
por: Baghdadi, Jonathan, et al.
Publicado: (2022)

Activation of the Chemokine Receptor CCR1 and Preferential Recruitment of Gαi Suppress RSV Replication: Implications for Developing Novel Respiratory Syncytial Virus Treatment Strategies
por: Li, Jiao, et al.
Publicado: (2022)

Protein arginine N-methyltransferase 4 (PRMT4) contributes to lymphopenia in experimental sepsis
por: Lai, Yandong, et al.
Publicado: (2023)

Lung directed antibody gene transfer confers protection against SARS-CoV-2 infection
por: Du, Yue, et al.
Publicado: (2022)

C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial
por: Temesgen, Zelalem, et al.
Publicado: (2023)

Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody response
por: Shields, Adrian M, et al.
Publicado: (2021)

Respiratory tract infections (RTIs) in primary care: narrative review of C reactive protein (CRP) point-of-care testing (POCT) and antibacterial use in patients who present with symptoms of RTI
por: Cooke, Jonathan, et al.
Publicado: (2020)

Complete Genome Sequences of Two Human Respiratory Syncytial Virus Genotype A Strains from India, RSV-A/NIV1114046/11 and RSV-A/NIV1114073/11
por: Choudhary, Manohar Lal, et al.
Publicado: (2013)

Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases
por: Harboe, Zitta Barrella, et al.
Publicado: (2022)

Impact of social deprivation on clinical outcomes of adults hospitalised with community-acquired pneumonia in England: a retrospective cohort study
por: Lawrence, Hannah, et al.
Publicado: (2022)

Combination Therapy Using Monoclonal Antibodies against Respiratory Syncytial Virus (RSV) G Glycoprotein Protects from RSV Disease in BALB/c Mice
por: Caidi, Hayat, et al.
Publicado: (2012)

Evidence against the Human Metapneumovirus G, SH, and M2-2 Proteins as Bona Fide Interferon Antagonists
por: Groen, K., et al.
Publicado: (2022)

Two RSV Platforms for G, F, or G+F Proteins VLPs
por: Ha, Binh, et al.
Publicado: (2020)

RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses
por: Su, Caixia, et al.
Publicado: (2022)

Prevalence of swallow, communication, voice and cognitive compromise following hospitalisation for COVID-19: the PHOSP-COVID analysis
por: Dawson, Camilla, et al.
Publicado: (2023)

The Central Conserved Region (CCR) of Respiratory Syncytial Virus (RSV) G Protein Modulates Host miRNA Expression and Alters the Cellular Response to Infection
por: Bakre, Abhijeet A., et al.
Publicado: (2017)

Genome Sequences of Mycobacteriophages Jane and Sneeze, New Members of Cluster G
por: Mageeney, Catherine M., et al.
Publicado: (2017)

Complete Genomic Sequence for an Avian Group G Rotavirus from South Africa
por: Stucker, Karla M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hrcb8almde98bif5ucm9i76upi